NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on severe depression, bipolar depression, post-traumatic stress disorder, and related suicidal ideation. Its current pipeline centers on NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. The company also works on adjacent neuropsychiatric and respiratory care initiatives through its broader portfolio and operating segments. NRx Pharmaceuticals, Inc. serves a specialized role in psychiatry by targeting high-unmet-need conditions where conventional treatment options may be limited or insufficient. Headquartered in Wilmington, Delaware, it operates as a focused developer of novel therapeutics for complex mental health and neurological indications.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Jonathan C. Javitt M.D., M.P.H.

Employees

29

Headquarters

Wilmington, DE, United States

Website

www.nrxpharma.com